Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 55.49B +71.2% |
| Revenue (ttm) | 51.84B -1.7% |
| Net Income | -1.99B |
| EPS | -2.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.40 |
| Dividend | 0.02 (0.16%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 667,652 |
| Open | 14.18 |
| Previous Close | 14.11 |
| Day's Range | 14.01 - 14.23 |
| 52-Week Range | 7.48 - 15.23 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 15.90 (+13.41%) |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BAYRY stock is "Buy." The 12-month stock price target is $15.9, which is an increase of 13.41% from the latest price.
News
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the Euro...
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with strong performance in Crop Science and new pharma products offsetting declines in mature brands. Litigation risks eased after a favorable U.S. Supreme Court ruling, and capital structure was strengthened by Apollo's equity investment and new bond issuance.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Slides: Q2 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Bayer Aktiengesellschaft Q2 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN said first-half sales rose 3% on a currency- and portfolio-adjusted basis to €24.3 billion, as growth in Crop Science and Consumer Health offset pressure in parts of...
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with margin gains in Crop Science and resilience in Pharma. Litigation risk eased after a favorable Supreme Court ruling, and capital structure was strengthened by a EUR 3 billion Apollo investment and $5 billion bond issue.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Swings to Net Profit on Smaller Litigation Charges
The company said its 2026 sales and earnings forecasts were unchanged when adjusted for currency changes, and that year-end net debt would be lower than originally projected.
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched...
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings toge...
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to...
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
Bayer gets €3 billion in Apollo deal for contraceptives unit
Bayer said on Friday it had secured €3 billion ($3.4 billion) in equity from Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, aiming to bolster i...
Bayer fuels break-up talk as Roundup business put into separate unit
Bayer BAYGn.DE said on Thursday it was consolidating its U.S. Roundup business in a new unit, less than a week after scoring a major legal victory that blocked thousands of state-court lawsuits relat...
Bayer seeks US duties on Chinese-made glyphosate, angering farmers
June 30 (Reuters) - Bayer asked Washington to impose duties on glyphosate, the chemical used in the company's weedkiller Roundup, imported from China, saying it was being sold at artificially low pr...
Bayer Gets New Life After Supreme Court's Roundup Ruling
A high-court victory gives the German company more leverage to settle outstanding cases.
Bayer's stock jumps after Supreme Court sides with Roundup weedkiller manufacturer
The court ruled that states cannot have differing labeling warning rules than federal law requires.
Bayer wins Supreme Court case making it harder to sue over glyphosate in Monsanto's Roundup
The Supreme Court in a 7-2 decision on Thursday said Bayer cannot be sued over state-level claims that the company failed to warn of cancer risks from its weedkiller Roundup and its chemical glyphosat...
Bayer Not Liable After Man Claimed Weedkiller Caused His Cancer, Supreme Court Rules
The Supreme Court ruled in favor of former agrochemical giant Monsanto on Thursday in a dispute over whether the company should have warned consumers about potential harms arising from its weed killer...
Bayer shares surge after U.S. Supreme Court rules in favour of company
Shares in Germany's Bayer surged by the most in 23 years on Thursday after the U.S. Supreme Court sided with the the company concerning lawsuits related its Roundup weedkiller.
Bayer Wins Supreme Court Challenge Over Roundup Litigation
The decision will help the company in its bid to resolve thousands of claims that the popular weedkiller caused cancer.